Overview

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to see if RAD001 can help to control the disease in patients with systemic mastocytosis (SM). The safety of this treatment will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Novartis Pharmaceuticals
Treatments:
Everolimus
Sirolimus